Overview
Dr Yoon-Kyo An is the “Head of Inflammatory Bowel Disease (IBD)” at Mater Hospital Brisbane and the “Clinical Lead of the IBD Clinical Trials Unit” at Mater Research, a world class centre of clinical and research excellence. The centre is among the largest IBD clinical research units in Australia. She is also a gastroenterologist who specialises in IBD, combining public and private practices at Mater Hospital Brisbane, Mater Private Hospital Brisbane, and Mater Private Hospital Redland. She holds a senior lecturer position at the University of Queensland. Dr An is a co-founder of digital healthcare education platform ‘GutTalk’, which aims to empower patients and communities by closing the communication and knowledge gap in Gut Health.
Dr An completed her Medical Science degree (BMedSc) at the University of Sydney and her Medical degree (MBBS) at the University of Queensland. She undertook her physician and advanced gastroenterology training at the Royal Brisbane and Women’s Hospital and Mater Hospital Brisbane. She completed a clinical and research fellowship in IBD at Mater Hospital Brisbane and completed the executive business and leadership program at the University of Oxford Said Business School. She is currently pursuing a PhD through the University of Queensland and an MBA through Griffith University.
Dr An is a passionate advocate for optimising patient outcomes through a holistic approach to care including personalised treatment plans to manage digestive health and incorporation of clinical and translational research. She is an active IBD clinician and researcher as well as a patient advocate. Her own research focusses on real-world effectiveness of biologic therapy in IBD and the use of intestinal ultrasound to monitor disease activity and predict responses to therapy. She drives collaborative research projects throughout Australia and is actively involved with the Australia New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC), the Gastroenterology Network for Intestinal Ultrasound (GENIUS) and the Gastroenterological Society of Australia (GESA).
Dr An has been successful in competitive research funding from industry and philanthropic organisations. She was the recipient of the inaugural GENIUS fellowship. She has affiliations with many Gastroenterology and IBD societies and has a national presence through her numerous symposia and conference presentations. She also serves on several Medical Advisory Boards including Chiesi, Bristol-Myers Squibb, and NPS Medicine Wise as well as sitting on the Council of Therapeutic Advisory Group. She is a GESA representative on the GP Aware Program committee and works collaboratively with Crohn’s and Colitis Australia (CCA).
Current Appointments
- 2021 – current: Executive Committee Member – Secretary, Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)
- 2020 – current: Scientific Committee Member, Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)
- 2020 – current: Board Member – Research Officer, Gastroenterology Network for Intestinal Ultrasound (GENIUS)
- 2020 – current: Executive Committee Member – IBD Liaison Officer, Young GESA Network, Gastroenterological Society of Australia (GESA)
- 2020 – current: Expert Advisory Group member, The Council of Therapeutic Advisory Groups (CATAG)
- 2020 – current: GESA representative, CCA-GESA GP Aware Program Committee, Crohn’s and Colitis Australia (CCA)
- 2020 – current: Expert Working Group Member, bDMARDs Gastroenterology Design Forum, NPS Medicine Wise
- 2020 – current: Stakeholder Panel (GESA representative), Value in Prescribing bDMARDs Program, NPS Medicine Wise
Publications
-
Journal Article: Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero
Prentice, Ralley, Flanagan, Emma, Wright, Emily K., Gibson, Peter R., Rosella, Sam, Rosella, Ourania, Begun, Jakob, An, Yoon-Kyo, Lawrance, Ian C., Kamm, Michael A., Sparrow, Miles, Goldberg, Rimma, Prideaux, Lani, Vogrin, Sara, Kiburg, Katerina V., Ross, Alyson L., Burns, Megan and Bell, Sally J. (2024). Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2024.02.025
-
Davies, J, Amiss, A, Khoo, E, An, Y K and Begun, J (2024). P034 Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial. Journal of Crohn's and Colitis, 18 (Supplement_1), i292-i292. doi: 10.1093/ecco-jcc/jjad212.0164
-
Journal Article: P1064 Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib
Gilmore, R, Fernandes, R, Hartley, I, Arzivian, A, Leong, R, Andrew, B, Vasudevan, A, Greeve, T, Moore, G, Kim, S, Lightowler, D, Singh, A, Mahy, G, Mithanthaya, A, Venugpal, K, Han, S, Bryant, R, West, J, Segal, J, Christensen, B, Ding, N J, An, Y K and Begun, J (2024). P1064 Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. Journal of Crohn's and Colitis, 18 (Supplement_1), i1913-i1913. doi: 10.1093/ecco-jcc/jjad212.1194
Publications
Journal Article
-
Prentice, Ralley, Flanagan, Emma, Wright, Emily K., Gibson, Peter R., Rosella, Sam, Rosella, Ourania, Begun, Jakob, An, Yoon-Kyo, Lawrance, Ian C., Kamm, Michael A., Sparrow, Miles, Goldberg, Rimma, Prideaux, Lani, Vogrin, Sara, Kiburg, Katerina V., Ross, Alyson L., Burns, Megan and Bell, Sally J. (2024). Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2024.02.025
-
Davies, J, Amiss, A, Khoo, E, An, Y K and Begun, J (2024). P034 Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial. Journal of Crohn's and Colitis, 18 (Supplement_1), i292-i292. doi: 10.1093/ecco-jcc/jjad212.0164
-
Gilmore, R, Fernandes, R, Hartley, I, Arzivian, A, Leong, R, Andrew, B, Vasudevan, A, Greeve, T, Moore, G, Kim, S, Lightowler, D, Singh, A, Mahy, G, Mithanthaya, A, Venugpal, K, Han, S, Bryant, R, West, J, Segal, J, Christensen, B, Ding, N J, An, Y K and Begun, J (2024). P1064 Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. Journal of Crohn's and Colitis, 18 (Supplement_1), i1913-i1913. doi: 10.1093/ecco-jcc/jjad212.1194
-
Kim, D H, Park, S H, Kim, H S, Kim, S J, Kim, K O, Lee, Y J, Song, E M, Kim, E S, Lee, H S, An, Y K, Begun, J, Ruddick-Collins, L, Fernandes, R, Liu, J, Cao, Q, Kobayashi, T and Wei, S C (2024). P425 Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. Journal of Crohn's and Colitis, 18 (Supplement_1), i876-i877. doi: 10.1093/ecco-jcc/jjad212.0555
-
Argollo, M, An, Y K, Balderramo, D, Nahla, A, Kuo, C J, Fadeeva, O and Uy, E (2024). P520 Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experiment. Journal of Crohn's and Colitis, 18 (Supplement_1), i1026-i1027. doi: 10.1093/ecco-jcc/jjad212.0650
-
Kim, S J, Kim, D H, Park, S H, Kim, K O, Lee, Y J, Song, E M, Kim, E S, Lee, H S, An, Y K, Begun, J, Ruddick-Collins, L, Fernandes, R, Liu, J, Cao, Q, Kobayashi, T and Wei, S C (2024). P762 Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. Journal of Crohn's and Colitis, 18 (Supplement_1), i1423-i1425. doi: 10.1093/ecco-jcc/jjad212.0892
-
P854 Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis
Khoo, E, Amiss, A, Ding, J N, Bryant, R, Mohsen, W, Connor, S, Leung, R, Croft, A, Lynch, K, Sparrow, M, De Cruz, P, An, Y K, Holtmann, G and Begun, J (2024). P854 Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Journal of Crohn's and Colitis, 18 (Supplement_1), i1583-i1583. doi: 10.1093/ecco-jcc/jjad212.0984
-
Khoo, Emi, Lee, Andrew, Neeman, Teresa, An, Yoon‐Kyo and Begun, Jakob (2023). Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment. JGH Open, 7 (12), 899-907. doi: 10.1002/jgh3.13000
-
Chetwood, J. D., Gupta, S., Subramaniam, K., De Cruz, P., Moore, G., An, Y. K., Connor, S. J., Kermeen, M., Paramsothy, S. and Leong, R. W. (2023). Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature. Expert Opinion on Drug Safety, 23 (4), 1-8. doi: 10.1080/14740338.2023.2278686
-
Gilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115
-
Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). 1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL. Gastroenterology, 164 (6), S-221. doi: 10.1016/s0016-5085(23)01488-9
-
An, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). Mo1722 REDUCTION OF BOWEL WALL THICKNESS AND DOPPLER SIGNALS AS EARY AS 36 HOURS PREDICTS CORTICOSTEROID RESPONSE IN A MULTI-CENTRE PROSPECTIVE COHORT OF ACUTE SEVERE ULCERATIVE COLITIS: USUC STUDY INCLUDING GENIUS COHORT. Gastroenterology, 164 (6), S-879. doi: 10.1016/s0016-5085(23)03032-9
-
Pudipeddi, A, Paramsothy, S, Kariyawasam, V, Paramsothy, R, Ghaly, S, Haifer, C, An, Y K, Begun, J, Connor, S, Corte, C, Ward, M, De Cruz, P, Fung, C, Redmond, D and Leong, R W (2023). P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. Journal of Crohn's and Colitis, 17 (Supplement_1), i542-i543. doi: 10.1093/ecco-jcc/jjac190.0543
-
Malloy, Reuben, Fernandes, Richard, Begun, Jakob and An, Yoon-Kyo (2022). Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 15 (12) 252140. doi: 10.1136/bcr-2022-252140
-
De Gregorio, Michael, Lee, Tanya, Krishnaprasad, Krupa, Amos, Gregory, An, Yoon-Kyo, Bastian-Jordan, Matthew, Begun, Jakob, Borok, Nira, Brown, Dougal J. M., Cheung, Wa, Connor, Susan J., Gerstenmaier, Jan, Gilbert, Lauren E., Gilmore, Robert, Gu, Bonita, Kutaiba, Numan, Lee, Allan, Mahy, Gillian, Srinivasan, Ashish, Thin, Lena, Thompson, Alexander J., Welman, Christopher J., Yong, Eric X. Z., De Cruz, Peter, van Langenberg, Daniel, Sparrow, Miles P. and Ding, Nik S. (2021). Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas. Clinical Gastroenterology and Hepatology, 20 (6), 1306-1314. doi: 10.1016/j.cgh.2021.07.053
-
Haifer, Craig, Srinivasan, Ashish, An, Yoon‐Kyo, Picardo, Sherman, Langenberg, Daniel, Menon, Shankar, Begun, Jakob, Ghaly, Simon and Thin, Lena (2020). Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Medical Journal of Australia, 214 (3) mja2.50824, 128-133. doi: 10.5694/mja2.50824
-
Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography
Flanagan, Emma, Wright, Emily K., Begun, Jakob, Bryant, Robert V., An, Yoon-Kyo, Ross, Alyson L., Kiburg, Katerina V. and Bell, Sally J. (2020). Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography. Journal of Crohn's and Colitis, 14 (10), 1405-1412. doi: 10.1093/ecco-jcc/jjaa082
-
An, Yoon‐Kyo, Prince, David, Gardiner, Fergus, Neeman, Teresa, Linedale, Ecushla C., Andrews, Jane M., Connor, Susan and Begun, Jakob (2019). Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis. Medical Journal of Australia, 211 (10) mja2.50384, 461-467. doi: 10.5694/mja2.50384
-
Rajagopalan, Arvind, Sathananthan, Dharshan, An, Yoon‐Kyo, Van De Ven, Lucinda, Martin, Serena, Fon, James, Costello, Samuel P, Begun, Jakob and Bryant, Robert V (2019). Gastrointestinal ultrasound in inflammatory bowel disease care: patient perceptions and impact on disease‐related knowledge. JGH Open, 4 (2) jgh3.12268, 267-272. doi: 10.1002/jgh3.12268
-
Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis
Choy, Matthew C., Seah, Dean, Faleck, David M., Shah, Shailja C., Chao, Che-Yung, An, Yoon-Kyo, Radford-Smith, Graham, Bessissow, Talat, Dubinsky, Marla C., Ford, Alexander C., Churilov, Leonid, Yeomans, Neville D. and De Cruz, Peter P. (2019). Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis. Inflammatory Bowel Diseases, 25 (7), 1169-1186. doi: 10.1093/ibd/izy383
-
Predicting response after infliximab salvage in acute severe ulcerative colitis
Choy, Matthew C., Seah, Dean, Gorelik, Alexandra, An, Yoon-Kyo, Chen, Cheng-Yu, Macrae, Finlay A., Sparrow, Miles P., Connell, William R., Moore, Gregory T., Radford-Smith, Graham, Van Langenberg, Daniel R. and De Cruz, Peter (2018). Predicting response after infliximab salvage in acute severe ulcerative colitis. Journal of Gastroenterology and Hepatology, 33 (7), 1347-1352. doi: 10.1111/jgh.14072
Conference Publication
-
Australian consensus on ustekinumab in Crohn's disease
Begun, J., An, Y-K, Bryant, R., Christensen, B., Leong, R., Studd, C. and Thin, L. (2023). Australian consensus on ustekinumab in Crohn's disease. HOBOKEN: WILEY.
-
Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopal, K., Han, S., Bryant, R., Corte, C., Ding, J. N., An, Y-K and Begun, J. (2023). Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis. HOBOKEN: WILEY.
-
Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Moore, G., Gazelakis, K., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Judge, C., Ngoi, B., Lynch, K., Begun, J. and An, Y-K (2023). Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC. HOBOKEN: WILEY.
-
Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitis
Rice, K., Fernandes, R., Hendy, P., Khoo, E., Walker, N., Howlett, M., An, Y-K and Begun, J. (2023). Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitis. HOBOKEN: WILEY.
-
Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. HOBOKEN: WILEY.
-
Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease
Tan, W. L., Barr, E., Pham, H., Fernandes, R., Khoo, E., An, Y-K and Begun, J. (2023). Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease. HOBOKEN: WILEY.
-
Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Gazelakis, K., Moore, G., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Lynch, K., Ngoi, B., Judge, C., Kim, D. H., Kim, H. S., Lee, H. S., Kim, K. O., Lee, Y. J., Kim, S-J, Lee, J., Song, E. M., Park, S. H. ... An, Y-K (2023). Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC. HOBOKEN: WILEY.
-
Etchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. HOBOKEN: WILEY.
-
Fernandes, R., Harris, H., Khoo, E., Gilmore, R., Howlett, M., Walker, N., Hendy, P., Begun, J. and An, Y-K (2023). Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound. HOBOKEN: WILEY.
-
Etchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. HOBOKEN: WILEY.
-
Tan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. HOBOKEN: WILEY.
-
Anandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. HOBOKEN: WILEY.
-
Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y-K, Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F. and Leong, R. (2023). Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial. HOBOKEN: WILEY.
-
An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Giri, Rabina, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.
-
An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Hai Pham, , Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.
-
An, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). REDUCTION OF BOWEL WALL THICKNESS AND DOPPLER SIGNALS AS EARY AS 36 HOURS PREDICTS CORTICOSTEROID RESPONSE IN A MULTI-CENTRE PROSPECTIVE COHORT OF ACUTE SEVERE ULCERATIVE COLITIS: USUC STUDY INCLUDING GENIUS COHORT. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.
-
Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.
-
An, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. OXFORD: OXFORD UNIV PRESS.
-
An, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A. and Begun, J. (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. OXFORD: OXFORD UNIV PRESS.
-
Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. OXFORD: OXFORD UNIV PRESS.
-
An, Y.K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744
-
An,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard , Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953
-
Risks of under-treating and over-treating disease
An, Yoon-Kyo (2021). Risks of under-treating and over-treating disease. IBD 2020: Right Therapy, Right Patient, Right Time#Choosing Wisely, Proceedings of the Takeda IBD Symposium, Virtual, 5 September 2020. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.15458
-
An, Y., Prince, D., Gardiner, F., Linedale, E., Andrews, J., Connor, S. and Begun, J. (2019). Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, South Australia, 8-10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14803
-
Haifer, C., Srinivasan, A., Menon, S., An, Y., Picardo, S., Van Langenberg, D., Begun, J., Ghaly, S. and Thin, L. (2019). Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, SA, Australia, 8–10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14801
-
Demyelination during infliximab therapy for crown's disease
An, Y. K., Allsop, S., Daveson, K.L. and Daveson, A. J. M. (2016). Demyelination during infliximab therapy for crown's disease. Australian Gastroenterology Week, Adelaide, SA, Australia, 10–12 October 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.13522
-
The incidence of 30-day adverse events after colonoscopy in an IBD population
An, Y. K., Wong, J., You, I. S., Mortimore, M., Hewett, D. G., Appleyard, M. N. and Begun, J. (2016). The incidence of 30-day adverse events after colonoscopy in an IBD population. Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Adelaide, South Australia, Australia, 10–12 October 2016. HOBOKEN: WILEY-BLACKWELL. doi: 10.1111/jgh.13522
-
A systematic analysis of complication rates of colonoscopy in a teaching hospital
An, Y. K., Hewett, D. G., Vandeleur, A. E. and Appleyard, M. N. (2012). A systematic analysis of complication rates of colonoscopy in a teaching hospital. Digestive Disease Week (DDW), San Diego, CA, USA, May 19-22, 2012. NEW YORK: MOSBY-ELSEVIER.
-
A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital
Finch, A., An, Y., Hewett, D. and Appleyard, M. (2012). A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital. RACP Future Directions in Health Congress 2012, Brisbane, QLD, Australia, 6-9 May 2012. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1445-5994.2012.02780.x
-
The impact of carbon dioxide insufflation on abdominal pain after colonoscopy
Finch, A., An, Y., Hewett, D. and Appleyard, M. (2012). The impact of carbon dioxide insufflation on abdominal pain after colonoscopy. RACP Future Directions in Health Congress 2012, Brisbane QLD, Australia, 6-9 May 2012. Richmond Vic., Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1445-5994.2012.02780.x
-
The impact of carbon dioxide insufflation on abdominal pain after colonoscopy
An, Y. K., Hewett, D. G. and Appleyard, M. N. (2012). The impact of carbon dioxide insufflation on abdominal pain after colonoscopy. Digestive Disease Week (DDW), San Diego Ca, May 19-22, 2012. NEW YORK: MOSBY-ELSEVIER.
-
A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital
An, Y. K., Hewett, D. G., Sexton, J., Vandeleur, A. and Appleyard, M. N. (2011). A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital. Australian Gastroenterology Week 2011, Brisbane, Qld., Australia, 12-15 September 2011. Richmond, Vic., Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1746.2011.06821.x
-
The impact of carbon dioxide insufflation on abdominal pain after colonoscopy
An, Y. K., Hewett, D. G. and Appleyard, M. N. (2011). The impact of carbon dioxide insufflation on abdominal pain after colonoscopy. Australian Gastroenterology Week 2011, Brisbane, Australia, 12-15 September 2011. MALDEN: MOSBY-ELSEVIER.
